19 international patents comprised of 18 items on imprinted genes involving twelve cancer types and 1 item on anti-tumor compound have been applied with PCT.

18 domestic patents comprised of 17 items on imprinted genes involving twelve cancer types and 1 item on anti-tumor compund have been applied with SIPO.

Research study entitled ‘High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules ’ was published in the Journal of Clinical Oncology on November 15, 2022.

Research study entitled ‘Epigenetic Imprinting Alterations as Effective Diagnostic Biomarkers for Early-Stage Lung Cancer and Small Pulmonary Nodules’ was published in the Clinical Epigenetics journal on December 14, 2021.

Abstract entitled ‘Intronic Noncoding RNA Expression of DCN is Related to Cancer-Associated Fibroblasts and NSCLC Patients’ Prognosis’ by Jian Zhou et al was accepted for presentation at the IASLC World Conference for Lung Cancer on March 1, 2021.

Abstract entitled ‘Epigenetic Imprinted Genes as Biomarkers for the Proactive Detection and Accurate Presurgical Diagnosis of Small Lung Nodules’ by Ning Zhou et al was accepted for presentation at the IASLC World Confrence for Lung Cancer on March 1, 2021.

Abstract entitled ‘Effect of Epigenetic Imprinting Biomarkers in Urine Exfoliated Cells (UEC) on the Diagnostic Accuracy of Low-Grade Bladder Cancer’ by Ning Zhou et al was accepted for presentation at the ASCO 2020 Annual Meeting on May 25, 2020.

Abstract entitled ‘Epigenetic Imprinted Gene Biomarkers Significantly Improve the Accuracy of Presurgical Bronchoscopy Diagnosis of Lung Cancer’ by Jian Zhou et al was accepted for presentation at the ASCO 2020 Annual Meeting on May 25, 2020.

Research study entitled ‘Novel Visualized Quantitative Epigenetic Imprinted Gene Biomarkers Diagnose the Malignancy of Ten Cancer Types’ was published in the Clinical Epigenetics journal on May 24, 2020.

Abstract entitled ‘Quantitative Chromogenic Imprinted Gene In Situ Hybridization (QCIGISH) Technique Could Diagnose Lung Cancer Accurately’ by Jian Zhou et al was accepted for presentation at the ATS 2020 Internal Conference on May 10, 2020.

Abstract entitled 'A Quantitative Chromogenic Technique for Imprinted Gene In Situ Hybridization (IG-ISH) - A New Addition for Enhanced Accuracy in Presurgical Diagnosis of Thyroid Cancers' was presented by Rulong Shen et al. during the USCAP 109th Annual Meeting held on February 29, 2020.

Abstract entitled 'Epigenetic Panel of Imprinted Genes Can Enhance the Accuracy of FNA Cytopathology for Thyroid Cancer' was presented by Rulong Shen et al. during the ATA 2019 Annual Meeting held on October 31, 2019.

Abstract entitled 'Epigenetic Imprinted Genes Can Be Used as Biomarkers for Malignant Tumors' was presented by Ning Zhou et al. during the 2019 CSCO Annual Meeting held on September 18, 2019.

Abstract entitled 'A Panel of Novel Epigenetic Imprinted Genes Improves Early Diagnosis of Lung Cancers' was presented by Jian Zhou et al. during the 2019 CSCO Annual Meeting held on September 18, 2019.

Abstract entitled 'Imprinted Genes Predict Non-Small Cell Lung Cancer Prognosis' was presented by Jian Zhou et al. during the IASLC World Conference for Lung Cancer held on September 7, 2019.

Abstract entitled 'In-Situ Hybridization Visual Scoring of Epigenetic Imprinting Genes Improves Early Diagnosis and Grading of Lung Cancers' was presented by Rex Yung et al. during the IASLC World Conference for Lung Cancer held on September 7, 2019.

Presentation entitled 'ISH Chromogenic Staining Non-Coding Nascent RNA for Detection of Lung Cancer Imprinted Genes' was delivered by Rex Yung et al. during the 2019 Lung Cancer SPORE held on June 13, 2019.

Presentation entitled 'Novel Epigentic Biomarkers for Lung Cancers' was delivered by Chunxue Bai et al. during the ATS 2019 International Conference held on May 18, 2019.

Presentation entitled 'Imprinting Diagnostics for Evaluation of Early Stage Lung Cancers' was delivered by Chunxue Bai et al. during the 2018 International Symposium on Respiratory Diseases and ATS Joint Conference held on November 16, 2018.